Emkay Global Financial' research report on Dr Reddys
Dr Reddy’s’ Form 20-F disclosures indicate that gRevlimid sales in FY26 were closer to our base-case estimate (~$300mn). However, assuming muted growth in the company’s base oncology portfolio since FY22, gRevlimid contribution would have been higher by ~$100mn in FY26 vs our base case. We have maintained the view that the debate around the magnitude of the Semaglutide opportunity for Dr Reddy’s (please connect with us for our detailed assumptions) is only meaningful if the ex-gRevlimid US base settles at ~$900mn-$1bn. To that extent, we now have greater clarity around the FY26 US base business levels (lower bound closer to $900mn) even as our and the street’s gRevlimid EBITDA contribution assumptions for FY26 might still prove to be conservative. Besides, price erosion in global generics in FY26 remained in the high single digit. We argue for measured optimism around an on-time approval for Abatacept (IV US launch base case - 4QFY27), given that a majority of the past CRLs issued by the USFDA to first biosimilar filers cited facility-linked queries (Exhibit 1) and Dr Reddy’s’ Bachupally facility has faced repeated challenges in meeting the FDA’s expectations over the last 3 years (US CMO option more likely for the subcutaneous filing). Note that even the company’s partnered biosimilar filings such as Denosumab have faced a similar set of challenges (delayed by a year vs the company’s initial expectations).
Outlook
We roll forward to Jun-28E EPS and revise up our TP by 8.3% to Rs1,300 from Rs1,200 earlier; retain REDUCE.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Dr Reddys - 0107026 - emkay